NorthLight Life Science Solutions

NorthLight Life Science Solutions was a Swedish life science services company focused on delivering clinical trials through high-volume, high-quality clinical centers in Scandinavia. Public references describe it as a related company of MCG Technology Group and indicate involvement in executing a Betagenon clinical study in heart failure with preserved ejection fraction. The company appears to have operated as a clinical development services provider rather than a therapeutic product developer, so there is no identifiable proprietary drug pipeline. Swedish business registry and credit-reporting sources indicate the legal entity entered bankruptcy on April 19, 2023.